ABSTRACT
A 50-year-old man presented with fecaluria and was diagnosed with sigmoid colon cancer with a colovesical fistula. Total bladder resection was determined to be necessary for curative resection at the time of diagnosis. In anticipation of bladder preservation, 6 courses of mFOLFOX6 plus panitumumab were administered after transverse colostomy, resulting in marked tumor regression and a decision to proceed with surgery. The patient underwent robotic-assisted low anterior resection of the rectum and partial cystectomy, which yielded pathological radical treatment. We report a case of sigmoid colon cancer with a colovesical fistula complicated by bladder invasion, in which preoperative chemotherapy was effective and total cystectomy was avoided, allowing bladder preservation.
Subject(s)
Intestinal Fistula , Rectal Neoplasms , Sigmoid Neoplasms , Humans , Male , Middle Aged , Intestinal Fistula/diagnosis , Intestinal Fistula/etiology , Neoadjuvant Therapy , Rectal Neoplasms/drug therapy , Rectal Neoplasms/surgery , Rectal Neoplasms/pathology , Rectum/pathology , Sigmoid Neoplasms/complications , Sigmoid Neoplasms/drug therapy , Sigmoid Neoplasms/surgeryABSTRACT
The patient underwent sigmoidectomy with D3 lymph node dissection and partial bladder resection for sigmoid colon cancer(cT4bN1M0, cStage â ¢a), after preoperative chemotherapy with mFOLFOX plus panitumumab, and FOLFOXIRI plus bevacizumab. Postoperative adjuvant chemotherapy was performed by 8 courses of CAPOX. He relapsed hilar lymph nodes and peritoneal dissemination after 13 months after surgery, he underwent resection of the recurrent lesions. Four months after, he developed recurrence in liver and peritoneum. Although he was treated with FOLFIRI plus ramucirumab or aflibercept, resulted in progression of disease, then he received trifluridine tipiracil hydrochloride plus bevacizumab. At this point, the Japanese health insulance had started to cover pembrolizumab, this therapy was started as the fourth chemotherapy after the diagnosis of high frequency microsatellite instability(MSI), and then tumor markers rapidly declined. He underwent 38 courses of pembrolizumab, the recurrent lesions both liver and peritoneum disappeared. He had stoma closure, peritoneal dissemination disappeared not only intraoperatively but also in histologically from the peritoneal scar. He has received pembrolizumab for 4 years without another recurrence. Here, we report a case of MSI-high sigmoid colon cancer in which long-term survival was achieved by pembrolizumab for recurrent lesions resistant to conventional chemotherapy.
Subject(s)
Antibodies, Monoclonal, Humanized , Sigmoid Neoplasms , Humans , Male , Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bevacizumab/therapeutic use , Sigmoid Neoplasms/drug therapy , Sigmoid Neoplasms/surgery , Sigmoid Neoplasms/pathologyABSTRACT
The case is a woman in her 60s. Sigmoid colon cancer surgery, liver metastasis surgery, and adjuvant chemotherapy were performed at another hospital 2 years ago. Later, she developed a metastasis in her liver and was recommended surgery, but she refused treatment and was transferred. Her liver metastasis had invaded the stomach and formed a giant gastric ulcer. This time she had an adhesive ileus and underwent laparoscopic surgery at our hospital. At that time, we observed the state of liver metastasis and gastric infiltration by laparoscopy, so we thought that palliative surgery was possible and recommended it. Although she initially refused treatment, the relative ease with which her ileus surgery was performed encouraged her to undergo palliative surgery. Laparoscopic-assisted gastrectomy and partial hepatectomy were performed, and she was discharged on hospital day 13 after surgery. She subsequently developed liver metastases and died 8 months after palliative surgery, although she was able to eat and maintain her ADL until the end of life. By staying close to the patient, we were able to lead the patient from refusal of surgery to palliative surgery, and we felt that we were able to make the patient reach a favorable end.
Subject(s)
Ileus , Liver Neoplasms , Sigmoid Neoplasms , Female , Humans , Ileus/etiology , Ileus/surgery , Liver Neoplasms/secondary , Sigmoid Neoplasms/drug therapy , Stomach/pathology , Middle Aged , AgedABSTRACT
A 51-year-old woman presented to our hospital complaining of a lower abdominal mass and dysuria. She was diagnosed with advanced sigmoid colon cancer. The tumor was large, involving the bladder, and occupying the pelvic cavity. She received neoadjuvant chemotherapy with 4 courses of mFOLFOX6, in addition to panitumumab. The treatment resulted in a marked reduction of the tumor. A laparoscopic sigmoid colon resection, total cystectomy, neobladder reconstruction, complete uterine and bilateral adnexa resection and partial ileal resection were performed. The histopathological diagnosis was ypT4b(bladder), ypN0, ypStage â ¡c, all with negative surgical margins. Adjuvant chemotherapy was not administered owing to the patient's refusal. She remained recurrence-free for 3 years of postoperative follow up.
Subject(s)
Sigmoid Neoplasms , Female , Humans , Middle Aged , Sigmoid Neoplasms/drug therapy , Sigmoid Neoplasms/surgery , Sigmoid Neoplasms/pathology , Neoadjuvant Therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Panitumumab/therapeutic use , Colon, Sigmoid/pathologyABSTRACT
A 64-year-old man was diagnosed with KRAS-mutant type sigmoid colon cancer with metastasis in the lung, liver, left adrenal gland, and para-aortic lymph node(T3N1M1b, Stage â £B[Union for International Cancer Control 8th edition]). Laparoscopic transverse colostomy was performed to treat colonic obstruction. Subsequently, a combination regimen of capecitabine plus oxaliplatin plus bevacizumab was administered. After 5 courses of chemotherapy, the S8 liver tumor disappeared completely. Sigmoidectomy, para-aortic lymph node dissection, and left adrenal gland resection were performed. After 3 months, right S3 segmental pneumonectomy and right S8 and S10 partial pneumonectomy were performed. R0 resection for the primary lesion and metastatic lesions of the chest and abdomen was achieved. Following the conversion surgery, he was administered the adjuvant chemotherapy regimen of uracil-tegafur plus Leucovorin. After 2 courses of chemotherapy, he presented to our hospital complaining of vomiting and dizziness. Contrast-enhanced magnetic resonance imaging revealed multiple brain metastases. Thus, we should be mindful of the possibility of brain metastasis in cases of unresectable colon cancer showing satisfactory response to chemotherapy with an indication of conversion surgery.
Subject(s)
Brain Neoplasms , Sigmoid Neoplasms , Male , Humans , Middle Aged , Sigmoid Neoplasms/drug therapy , Sigmoid Neoplasms/surgery , Sigmoid Neoplasms/pathology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bevacizumab/therapeutic use , Colon, Sigmoid/pathology , Lymph Nodes/pathology , Brain Neoplasms/drug therapy , Brain Neoplasms/surgeryABSTRACT
A male patient in his 80s underwent colonic stenting for obstructive sigmoid colon cancer with multiple liver metastases. With systemic chemotherapy for approximately 1 year, the liver metastasis disappeared, so laparoscopic sigmoid colectomy was performed for the primary lesion. No recurrence was observed for a while, although CT revealed liver metastasis in the liver S4, and radiofrequency ablation was performed. Radiation therapy was performed for the liver metastasis of liver S2 that subsequently appeared. After a recurrence-free period of approximately 2 years, a rapid regrowth of liver metastasis in liver S2 was observed. Thus, 4 years and 3 months after the initial diagnosis, lateral segmentectomy of the liver was performed. Five years have passed since the first visit, and he is alive without recurrence. The patient had obstructive colorectal cancer with unresectable liver metastasis, and as the obstruction was released by a colonic stent, systemic chemotherapy was prioritized. Hence, liver metastasis was controlled, and the primary lesion was resected. Furthermore, for the liver metastasis that appeared later, various loco-regional cancer therapies were provided to achieve a cancer-free state.
Subject(s)
Liver Neoplasms , Sigmoid Neoplasms , Humans , Male , Sigmoid Neoplasms/surgery , Sigmoid Neoplasms/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Liver Neoplasms/surgery , Liver Neoplasms/drug therapy , Colon, Sigmoid/pathologyABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Hyperammonemia/chemically induced , Fluorouracil/adverse effects , Sigmoid Neoplasms/drug therapy , Antineoplastic Agents/adverse effects , Brain Diseases/chemically inducedABSTRACT
BACKGROUND/AIMS: Colorectal neuroendocrine carcinoma is a rare neoplasm exhibiting fulminant progression and having poor prognosis. The purpose of this study is to verify the clinicopathologic characteristics of colorectal neuroendocrine carcinoma. METHODS: From June 1997 to December 2004 at Asan Medical Center, ten patients were originally identified as colorectal neuroendocrine carcinoma on the basis of H&E and immunohistochemical staining (IHC). Carcinoid tumors were excluded in this study. Medical records of thirteen patients were reviewed retrospectively. RESULTS: Ten patients (0.2%) with colorectal neuroendocrine tumors were identified from 4,512 patients with colorectal cancer; ten neuroendocrine carcinomas and three adenocarcinomas with neuroendocrine differentiation. Their median age was 60 (41-83) years. The subjects consisted of six males and seven females. Nine tumors were located in the rectum, two in the sigmoid, and each one in the transverse colon and cecum, respectively. Nine of ten neuroendocrine carcinomas expressed synaptophysin, but chromogranin A were expressed in four. All patients were advanced at the time of diagnosis, with AJCC TNM staging: stage IIIB (n=2), stage IIIC (n=3), and stage IV (n=8). The median survival for ten neuroendocrine carcinomas and three adenocarcinomas with neuroendocrine differentiation were 16.4 months and 30 months, respectively. Five patients who received chemotherapy showed median survival of 32 months (stage III) and 17.5 months (stage IV), whereas other five patients without chemotherapy died with a median survival of 6.2 months. CONCLUSIONS: Colorectal neuroendocrine tumors are extremely rare showing aggressive behavior biologically, i.e fulminant early distant metastasis. Nevertheless, improved survival may be achieved by aggressive multimodality therapy.
Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Adenocarcinoma/pathology , Biopsy , Carcinoma, Neuroendocrine/drug therapy , Chromogranin A/analysis , Colorectal Neoplasms/drug therapy , Drug Therapy, Combination , Neoplasm Metastasis , Retrospective Studies , Sigmoid Neoplasms/drug therapy , Synaptophysin/analysis , Biomarkers, Tumor/analysisABSTRACT
No disponible
Subject(s)
Male , Middle Aged , Humans , Angina Pectoris/chemically induced , Antimetabolites, Antineoplastic/adverse effects , Sigmoid Neoplasms/drug therapy , Sigmoid Neoplasms/complicationsABSTRACT
Clásicamente, la existencia de un tumor colorrectal conlleva su exéresis quirúrgica, con independencia de que se asocie o no a metástasis hepáticas. El importante desarrollo de las técnicas de imagen por un lado, la aparición de nuevas formas de quimioterapia y sus combinaciones, con diferentes vías de administración y eficacia progresivamente creciente por otro, junto al abordaje multidisciplinario en la toma de decisiones terapéuticas y la disponibilidad de tratamientos paliativos satisfactorios, obligan a matizar el papel de la cirugía y, en cualquier caso, el orden en el que se integra en la estrategia de tratamiento del cáncer colorrectal avanzado. Presentamos el caso de una paciente con neoplasia de sigma y múltiples metástasis hepáticas sincrónicas, que recibió inicialmente una quimioterapia intensiva, tras la cual pudo ser tratada con intención curativa de todas sus lesiones (primaria y metástasis) (AU)